What It Is
Tesamorelin is a synthetic analog of growth hormone-releasing hormone (GHRH), the hypothalamic signal that tells the pituitary gland to release growth hormone.[1] Rather than replacing growth hormone directly, it works upstream, prompting the pituitary to produce more of it.
In the US, tesamorelin is marketed as the prescription drug EGRIFTA SV, with an FDA-approved indication limited to reducing excess abdominal fat in adults with HIV-associated lipodystrophy, a condition involving abnormal fat redistribution linked to HIV and antiretroviral therapy.[2] That approval is narrow: it does not cover general weight loss, bodybuilding, anti-aging, or cosmetic use, and the label states tesamorelin is not indicated for weight-loss management.
How It Works
Tesamorelin binds to GHRH receptors on pituitary somatotroph cells, stimulating pulsatile growth hormone release, which drives production of insulin-like growth factor-1 (IGF-1) in the liver and other tissues.[1] This receptor-mediated pathway differs from injecting growth hormone directly, since it still relies on the body's own regulatory feedback loops.
The mechanism gives a plausible biological reason tesamorelin might reduce visceral fat, but mechanism alone does not guarantee an outcome for every person. IGF-1 elevation is a key marker clinicians track, both as a sign the drug is active and as a safety parameter.
What the Research Shows
The core evidence is a randomized trial published in the New England Journal of Medicine, which found tesamorelin reduced visceral adipose tissue in HIV-positive adults with abdominal fat accumulation compared with placebo — the data underlying FDA approval.[3] Imaging methods such as CT and MRI distinguished visceral fat from subcutaneous and liver fat, since a change in one compartment does not necessarily track with overall body weight.
Beyond the approved indication, trials in JAMA and The Lancet HIV examined tesamorelin's effect on liver fat in HIV-positive adults and reported reductions in hepatic fat.[4] These findings are promising but investigational; tesamorelin is not FDA-approved for fatty liver disease, and visceral-fat reductions have not been shown to persist after stopping treatment. Claims about muscle gain, performance, or anti-aging go well beyond what this evidence supports.
Safety & Side Effects
Labeling for EGRIFTA SV lists injection-site reactions (redness, itching, bruising, swelling) as common effects, along with joint and muscle pain, peripheral edema, and hypersensitivity reactions.[1] Because tesamorelin raises growth-hormone-axis activity, it can also cause glucose intolerance and elevated IGF-1, both of which warrant clinical monitoring.
- Fluid retention effects such as edema, arthralgia, or carpal-tunnel-type symptoms
- Glucose intolerance, relevant especially for people with diabetes risk
- Persistently elevated IGF-1, which may prompt treatment reassessment
- Hypersensitivity reactions to the drug or its components
The label also states that long-term cardiovascular safety and benefit have not been established, and contraindications include disruption of the hypothalamic-pituitary axis, active malignancy, and pregnancy.
Regulatory Status
Tesamorelin is FDA-approved, but only for one specific use: reducing excess abdominal fat in adults with HIV-associated lipodystrophy, sold under the brand EGRIFTA SV.[2] That is a genuinely narrow approval — it does not extend to general weight loss, anti-aging protocols, or athletic use, regardless of how the peptide is marketed elsewhere.
Compounded or research-labeled tesamorelin sold outside licensed pharmacy channels is a separate, unapproved category. The FDA has noted that compounded drug products do not undergo the same premarket review for safety, effectiveness, or quality as approved drugs, so such products should not be assumed equivalent to the studied and labeled version of tesamorelin.[5]
Tesamorelin Compared to Related Growth-Hormone Peptides
Tesamorelin is often discussed alongside other growth-hormone-axis compounds, but the comparisons obscure real regulatory differences. CJC-1295 is also a GHRH analog studied for prolonged growth hormone and IGF-1 stimulation, yet lacks any equivalent FDA-approved indication.[6] Ipamorelin works through a different, ghrelin-receptor-based pathway and remains a research-context compound rather than an approved therapy.
Recombinant growth hormone (somatropin) is a distinct, directly administered hormone with its own approved indications and is not interchangeable with tesamorelin's upstream approach. The clearest way to compare these compounds is by evidence quality and regulatory status, not shared discussion in online peptide communities.